A malaria vaccine that elicits long-lasting protection and is suitable for use in endemic areas
remains urgently needed. Here, we assessed the immunogenicity and prophylactic efficacy …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

Circumsporozoite protein (CSP) of Plasmodium falciparum is a protective human malaria
vaccine candidate. There is an urgent need for models that can rapidly down-select novel …

Circumsporozoite protein (CSP) of Plasmodium falciparum is a promising malaria vaccine
target. RTS, S, the most advanced malaria vaccine candidate consists of the central NANP …

Objective: The recent success of a Plasmodium falciparum malaria vaccine consisting of
circumsporozoite (CS) protein (CSP) T and B cell epitopes has rekindled interest in the …

There is a pressing need for safe and highly effective Plasmodium falciparum (Pf) malaria
vaccines. The circumsporozoite protein (CS), expressed on sporozoites and during early …

Plasmodium falciparum circumsporozoite protein (CSP) is a major sporozoite surface
protein and a key target of pre-erythrocytic malaria subunit vaccines. A full-length …

The circumsporozoite protein (CSP) of Plasmodium falciparum is a major surface protein,
which forms a dense coat on the sporozoite's surface. Preclinical research on CSP and …

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in
the search for a malaria vaccine in spite of being a target of inhibitory antibodies and …

Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that
resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 …